"DepoMed to Buy U.S. Rights to Nucynta From J&J Unit" at 4:31 p.m. ET Thursday and the update at 5:49 p.m. ET incorrectly linked the higher guidance to overall revenue instead of net product sales. DepoMed had projected about $113 million to $117 million in 2014 product sales and overall revenue of about $232 million to $242 million.

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Johnson and Johnson Charts.